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Contemporary studies illustrate that peripheral injuries acti-
vate glial components of the peripheral and central cellular 
circuitry. The subsequent release of glial stressors or activat-
ing signals contributes to neuropathic pain and neuroinflam-
mation. Recent studies document the importance of glia in 
the development and persistence of neuropathic pain and 
neuroinflammation as a connecting link, thereby focusing at-
tention on the glial pathology as the general underlying fac-
tor in essentially all age-related neurodegenerative diseases. 
There is wide agreement that excessive glial activation is a 
key process in nervous system disorders involving the re-
lease of strong pro-inflammatory cytokines, which can trig-
ger worsening of multiple disease states. This review will 
briefly discuss the recent findings that have shed light on the 
molecular and cellular mechanisms of glia as a connecting 
link between neuropathic pain and neuroinflammation.
[Immune Network 2012;12(2):41-47]
INTRODUCTION
Glia
٘Gliaٙ refers to a diverse set of specialized cell types that are 
found both in the peripheral nervous system (Schwann cells, 
satellite glia, perineural glia) and in the central nervous sys-
tem (CNS) (astrocytes, oligodendrocytes, microglia, and peri-
vascular glia) (1). Glial cells constitute 70% of the total cell 
population  in  the  brain  and  spinal  cord.  Glial cells  can  be 
subdivided into two primary categories: microglia, comprising 
5% to 10% of the glial population, and macroglia, which in-
clude  astrocytes  and  oligodendrocytes  (2).  Glial  cells  that 
were, up to several years ago, considered the ٘forgotten brain 
cells,ٙ or neglected stepchildren of neuroscience, now act as 
orchestrators in the tetrapartite synapse, and control of their 
activation  state  is  crucial  to  the  integrity  of  CNS  function. 
Recent technical advances and increased interest in elucidat-
ing  the  role  of  non-neuronal  cells  of  the  CNS  in  both  the 
physiological  and  pathophysiologial  processes  have  cata-
pulted these cells into the forefront of neuroscience research. 
Glial cells do not conduct nerve impulses, and they provide 
structural support for the brain, assisting in nervous system 
development,  repair  and  maintenance,  supplying  nutrients 
and  biosynthetic  products  to  neurons,  imparting  metabolic 
functions  to  neurons,  destroying  and  removing  injured  and 
dead  neurons  and,  finally,  regulating  the  neuronal  micro-
environment. The well known quote ٖthe neuron is the struc-
tural  and functional unit of the brainٗ has been challenged 
by  a  wealth  of  findings  which  have,  to  the  contrary,  in-
troduced  the  ٖneuronal-glial  complexٗ  as  the  structural  and 
functional  unit  of  the brain.  Glia regulate  brain  vasculature 
and  the  blood-brain  barrier,  modulating  ischemia  and 
migraines. Moreover, they are important in the repair of neu-
rons  after  injury  and  also  contribute  to  neuropathology  in 
neurodegenerative  diseases.  Microglia  can  either  protect  or 
damage  neurons  depending  on  where  and  how  they  are 
activated. Microglia are chronically engaged in repairing mi-
nor insults and that clinical diseases are observed only when 
t h e s e  r e p a i r  e f f o r t s  f a i l .  F u l l y  a c t i v a t e d  m i c r o g l i a  a r e  d e t r i -
mental to neurons, but other stages in the sequence of re-Glia in Neuropathic Pain and Inflammation
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active states may improve neuronal survival by releasing neu-
rotrophic factors or by removing excess glutamate from the 
extracellular  space  (3).  Glial  cells,  which  include  oligoden-
drocytes, astrocytes, and microglia, have been found to play 
key roles in neuroinflammation and neuropathic pain. Given 
that less is known about the involvement of oligodendrocytes, 
this paper will focus primarily on the role of astrocytes and 
microglial cells in neuroinflammation and neuropathic pain. 
In view of the neuroinflammation and neuropathic pain proc-
esses, activation of glial cells in the spinal dorsal horn, espe-
cially  microglia  and  astroglia,  plays  a  predominant  role. 
Furthermore,  astrocytes  and  microglia  are  known  to  play  a 
role in the development, spread, and potentiation of neuro-
pathic  pain  (4-12).
Neuroinflammation
Neuroinflammation is a normal and necessary process. In the 
acute  phase  after  injury,  neuroinflammation  is  tightly  con-
trolled. In its chronic phase or when directed against normal 
tissue  (in  an  autoimmune  response),  neuroinflammation  is 
detrimental when it manifests itself as multiple sclerosis (MS), 
amyotrophic lateral sclerosis (ALS), various types of dementia, 
Huntingtonٗs disease, or other diseases (13-16). A wide range 
of neurodegenerative diseases, including those affecting the 
CNS, such as Alzheimerٗs disease (AD), Parkinsonٗs disease 
(PD), ALS, and MS, are associated with chronic inflammation 
(17-21). Although inflammation may not be the initiating fac-
tor, emerging evidence in animal models suggests that sus-
tained  inflammatory  responses  involving  microglia  and  as-
trocytes contribute to disease progression (22). The activation 
of perivascular microglia and endothelial cells (lining the ca-
pillary bed), astrocytes (making up the blood-brain barrier), 
parenchymal microglia and astrocytes by the means of stress-
es, leads to the subsequent production of cytokines, cellular 
adhesion molecules, chemokines, and the expression of sur-
face antigens that enhance a CNS immune cascade. If left un-
checked, this neuroimmune activation can lead to the traffick-
ing of leukocytes into the perceived area of injury as a mech-
anism for neuroprotection. Therefore, neuroinflammation can 
be defined as the infiltration of immune cells into the site of 
injury in response to damage to the peripheral or CNS (23).
Neuropathic pain
Neuropathic pain, initiated or caused by primary lesions or 
dysfunction in the CNS (brain and spinal cord) or the periph-
eral  nervous  system  (nerves  outside  the  brain  and  spinal 
cord), having occurred following viral infection, trauma, cer-
tain  medications,  or  metabolic  insults,  and  many  diseases 
such as MS and stroke, is especially problematic because of 
its  severity,  chronicity,  and  resistance  to  simple  analgesics 
(24). The possible mechanisms of neuropathic pain could be 
classified as: a) chemical excitation of non-nociceptors, b) re-
cruitment of nerves outside the site of injury, c) excitotoxicity, 
d)  excess  sodium  channels,  e)  ectopic  discharge,  f)  central 
sensitization  maintained  by  peripheral  input,  and  g)  sym-
pathetic  involvement.
THE ROLE OF GLIA IN NEUROINFLAMMATION
The role of microglia in initiating or promoting inflammatory 
processes in the CNS by facilitating the recruitment of periph-
eral immune cells has been well documented (25-27). During 
the neuroinflammatory process, microglial cells release proin-
f l a m m a t o r y  m e d i a t o r s  s u c h  a s  c y t o k i n e s ,  m a t r i x  m e t a l -
loproteinases (MMP), reactive oxygen species (ROS), and ni-
tric oxide (NO). For a long time, glial cells have been consid-
ered to merely support the neuronal environment. However, 
the  innovative  research  in  the f i e l d  o f  n e u r o s c i e n c e  h a s  
strongly propelled glial cells as new players in neuroinflam-
mation and neuropathic pain. Neuroinflammation is a charac-
teristic feature of both acute and chronic CNS disorders and 
is a process that results primarily from the presence of chroni-
cally  activated  glial  cells  (astrocytes  and  microglia)  in  the 
brain, and is a common feature of several neurodegenerative 
conditions. Activated glia release a variety of neuroexcitatory 
substances that potentiate neurotransmission, especially pro-
inflammatory cytokines. Blocking glial activity may be a novel 
way of controlling neuropathic pain. Neuroinflammation in-
d u c e s  a  c o m p l e x  a n d  d y n a m i c  c h a n g e  i n  g l i a l  c e l l  p h e n o -
t y p e s .  O n e  o f  t h e  f i r s t  c e l l  t y p e s  t o  r e s p o n d  a r e  m i c r o g l i a l 
cells, which retract their processes and migrate towards the 
site of injury, where they release proinflammatory cytokines 
such  as  IL-1β,  TNF-α,  and  IL-6  (28-30). 
THE ROLE OF GLIA IN NEUROPATHIC PAIN
Neuropathic pain is a debilitating condition that affects mil-
lions of individuals worldwide. It is now thought that solely 
considering neuronal activity provides an incomplete under-
standing of the creation and maintenance of chronic neuro-
pathic pain (31). Glia have recently emerged as key contrib-
utors to pathological and chronic pain mechanisms and are Glia in Neuropathic Pain and Inflammation
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emerging  as  a  new  target  for  drug  development  (32,33). 
Spinal cord glial activation seems to be a common underlying 
m e c h a n i s m  t h a t  l e a d s  t o  p a t h o l o g i c a l  p a i n  i n  a  n u m b e r  o f  
pain syndromes with dramatically different aetiologies (for ex-
ample,  diabetic  neuropathy,  chemotherapy-induced  neuro-
pathy, peripheral nerve inflammation and trauma, and spinal 
cord inflammation) (34). Upon activation, both the astrocytes 
and microglia respond to and release a number of signaling 
molecules  which  have  protective  and/or  pathological  func-
tions. These include, among others, the classic immune sig-
nals: cytokines and chemokines. The role of glia in the CNS 
is intimately integrated with the functions of the other players 
in the tetrapartite synapse composed of pre- and post- syn-
aptic neurons, astrocytes, and microglial cells. In trauma or 
disease states, the spinal glia become activated and the dorsal 
horn neurons become hyperexcitable, contributing to sensi-
tized  neuronal-glial  circuits.  The  maladaptive  spinal  circuits 
directly affect synaptic excitability, including the activation of 
intracellular  downstream  cascades,  that  results  in  enhanced 
evoked and spontaneous activity in dorsal horn neurons lead-
ing  to  the  development  of  abnormal  pain  syndromes  (35).
INTERLINKING INFLAMMATION AND 
NEUROPATHIC PAIN
Inflammation is a component of the bodyٗs wisdom. Inflam-
mation  is  the  bodyٗs  f o r e m o s t  r e s p o n s e  t o  a n  i n j u r y  o r  
disease. Webster defines inflammation as ٘redness, swelling 
and fever in a local area of the body, often with pain and 
disturbed function, in reaction to an infection or to a physical 
or  chemical  injury.ٙ  Symptoms  of  inflammation  can  range 
from  mild  aches  to  sharp,  wrenching  pain  that  may  take 
oneٗs breath away. Inflammation in any part of our body is 
coupled with pain, due to the release of inflammatory media-
tors such as prostaglandin E2 (PGE2), the proinflammatory cy-
tokines TNF-α and IL-1β, and nerve growth factor (NGF). 
These  mediators,  produced  by  non-neural  cells  or  immune 
cells, can stimulate nociceptor terminals in the peripheral tis-
sue to increase pain sensitivity (36,37). Inflammation also oc-
curs  in  the  CNS  after  brain  trauma,  brain  infection,  and  in 
neurodegenerative diseases, such as AD, PD, and MS. This 
so-called neuroinflammation is characterized by the activation 
of glial cells (especially microglia and astrocytes) in the CNS 
and is an important contributor to the development of neuro-
degeneration by releasing inflammatory mediators from glial 
cells (38,39). This glia-mediated neuroinflammation also plays 
an important role in pain control under pathological condi-
tions.
    Although  multiple  conditions  may  generate  neuropathic 
pain, a common underlying mechanism is the presence of in-
flammation at the site of the damaged or affected nerve(s). 
This inflammatory response initiates a cascade of events re-
sulting in increased local perfusion, increased capillary per-
meability, and the concentration and activation of innate im-
mune cells at the site of tissue injury, irritation, or infection. 
Immunoactive  substances,  such  as  cytokines,  neurotrophic 
factors, and chemokines, released at the site of injury have 
local  actions  and  can  initiate  a  systemic  immune  response. 
The resultant neuroinflammatory environment can cause the 
activation  of  microglia  and  astrocytes  located  in  the  spinal 
cord  and  brain,  which  appear  to  play  a  prominent  role  in 
nociception  (40). 
    Current research suggests that microglia are involved in the 
early  development  of  neuropathic  pain,  whereas  astrocytes 
function to sustain neuropathic pain (12,41-43). The activa-
tion of spinal cord glia is both necessary and sometimes even 
sufficient for the development of persistent pain states asso-
ciated with various etiologies, including diabetic neuropathy, 
chemotherapy-induced  neuropathy,  peripheral  nerve  in-
flammation and trauma, and spinal cord inflammation (44-46). 
Both spinal astrocytes and microglia activate mitogen-activat-
ed protein kinases (MAPKs) to induce the synthesis and re-
lease of proinflammatory cytokines, such as IL-1β, IL-6, TNF-
α, PGE2, and NO (47,48). There is ample evidence that both 
astrocyte  and  microglia  activation  lead  to  pro-inflammatory 
responses with pathological effects, such as neuronal hyper-
excitability, neurotoxicity and chronic inflammation. Fig. 1 il-
lustrates  the  consequential  neuroinflammation  and  neuro-
pathic  pain  subsequent  to  the  neuronal  injury  via  the  glial 
cell  (microglial  and  astrocytic)  activation.
GLIA IN FORMALIN TEST & COMPLETE FREUND’S 
ADJUVANT (CFA)-INDUCED INFLAMMATORY PAIN 
MODEL
Animal models of inflammatory pain have been widely used 
to study the mechanisms of tissue injury that induced persis-
tent pain. The formalin test is the most predictive of the mod-
els for acute pain, it is predominantly used on rats and mice 
and involves moderate, continuous pain generated by injured 
tissue. In this way it differs from most traditional tests of noci-
ception  which  rely  on  brief  stimuli  of  threshold  intensity. Glia in Neuropathic Pain and Inflammation
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Figure 1. Diagram showing the neuroinflammation and neuropathic pain subsequent to the neuronal injury and glial cell (microglial and astrocytic)
activation. Following a peripheral injury, the synaptic projection of pain sensing neuron within the spinal cord releases ATP. Nearby microglial 
cells are drawn to the source of ATP and undergo morphological changes as they approach the source and become activated. Fully activated
microglial cells are localized around the pain sensing neuron and begin to interact with the neurons at a molecular level, releasing various
neuroinflammatory agents. These neuroinflammatory agents activate astrocytes. Upon activation, the astrocytes undergo hypertrophy and increased
production of neuroinflammatory agents are secreted into the synaptic cleft. Astrocyte activation in conjugation with microglial activation 
significantly depolarizes the neuron increasing its sensitivity and potentiating the neuroinflammation and neuropathic pain states. EAA, excitatory
amino acids.
Formalin injected beneath the footpad of a rat, mouse, or cat 
produces two phases of nocifensive behavior, characterized 
by the licking and flinching of the paw, that are separated 
by a short period of quiescence in which there is no apparent 
pain behavior (49,50). The first or ٘acuteٙ phase typically oc-
curs  in  the  first  5  min;  the  second  starts  from  15  min  and 
lasts about 40∼60 min after injection. The early phase seems 
to be caused predominantly by the direct activation of both 
the low-threshold mechanoreceptive and the nociceptive pri-
mary afferent fibers due to the peripheral stimulus (51). The 
late phase, also called the tonic phase, appears to be depend-
ent  on  the  combination  of  an  inflammatory  reaction  in  the 
peripheral tissue and functional changes in the dorsal horn 
of the spinal cord, popularly called central processing. These 
functional changes seem to be initiated by the C-fiber barrage 
during  the  early  phase  (52). 
    Complete  Freundٗs  adjuvant  (CFA)-induced  inflammatory 
p a i n  i s  v e r y  c o m m o n l y  u s e d  a s  a  m o d e l  f o r  c h r o n i c  i n -
flammatory pain. CFA contains heat-killed or inactivated and 
dried mycobacteria, which is a primary agent responsible for 
stimulating antibody production, but has also been attributed 
to a number of undesirable side effects (53). This assay has 
a good track record for predicting the effectiveness of com-
pounds as analgesic or anti-hyperalgesic agents as well as de-
fining the mechanism behind inflammatory pain. CFA is in-
jected into  one hind-paw  of the  animal. The CFA  injection 
in the footpad produces localized inflammation and persistent 
pain (54,55). Thermal hyperalgesia or  mechanical  allodynia 
associated with the inflammation are assessed by determining 
the hind-paw withdrawal latency. After the CFA injection into Glia in Neuropathic Pain and Inflammation
Mithilesh Kumar Jha, et al.
45 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 2 April 2012
the  footpad,  cutaneous  inflammation  appears  in  minutes  to 
hours and peaks within 5∼8 hours. The average time of on-
set is 2∼6 hours and persists for approximately 1∼2 weeks. 
The edema peaks around 24 hours after injection (56). For 
the induction of hind paw inflammation, mice receive (ipl.) 
injection  of  10μl  of  CFA  (diluted  with  PBS,  2  mg/ml 
Mycobacterium  tuberculosis).  The  CFA  produces  dose-de-
pendent inflammatory responses. Behavior testing in CFA-in-
j e c t e d  m i c e  i s  d o n e  b y  m e c h a n i c a l  s e n s i t i v i t y  t e s t i n g  u s i n g  
von  Frey  hairs  and  heat  sensitivity  testing. 
    Peripheral formalin injection induces two stages of microglial 
activation: p38 activation in spinal microglia plays key roles in 
central pain modulation in formalin test for both the early acute 
phase and the late secondary long-term pain state (57). These 
unique properties of spinal microglial activation in an animal 
model of pain will potentially help to further understand the 
contributions  of  spinal  microglia  to  acute  and  chronic  pain 
states. Both qualitative and quantitative analyses for the com-
parison of the effects of the peripheral CFA and formalin in-
jection on spinal microglia activation showed signs of micro-
glia activation on the ipsilateral side of the lumbar dorsal horn 
on  days  3,  7,  and  14  after  the  formalin  injection  was 
introduced. However, significant microglia morphological al-
teration  was  not  found  in  the  CFA  model.  At  the  injection 
site in the paw, the CFA injection induced considerably more 
inflammation than the formalin injection. Although spinal mi-
croglia  might  have  been  activated  morphologically  in  in-
flammatory  pain  models,  spinal  microglia  activation  was  not 
closely correlated with peripheral inflammation (58). Glial acti-
vation is a common feature of many diseases of the CNS (59). 
In the spinal cord, astrocytes are activated following periph-
eral  inflammation  or  the  nerve  injury  and  may  manifest  as 
increased expression of astrocytic markers such as glial fibril-
lary acidic protein (GFAP) (60,61). The peripheral injection 
of  CFA  increased  the  mRNA  and  protein  expression  of  the 
astrocytic marker GFAP in the bilateral anterior cingulate cor-
tex  (ACC).  The  inhibition  of  astroglial  function  by  an  as-
troglial toxin blocked the place-avoidance behavior, but not 
the paw withdrawal threshold, suggesting the involvement of 
astrocytes  in  the  ACC  as  the  affective  component  of  pain. 
Modulating the function of astrocytes in the ACC may provide 
a  new  strategy  for  the  prevention  of  chronic  pain-induced 
emotional  disturbances. 
CONCLUSION AND FUTURE PERSPECTIVES
Neurons  are  not  the  only  cell  type  in  the  nervous  system; 
∼90%  of  the  cells  in  our  brain  are  glia.  Glia,  which  until 
recently were thought to be passive support cells for the neu-
rons, are now considered to be, not only the link between 
neuroinflammation  and  neuropathic  pain,  but  also  an  im-
portant link between the immune and nervous systems under 
inflammatory and traumatic conditions. Microglia, not ٖbornٗ 
in the nervous system but formed by the transformation of 
certain  white  blood  cells  called  macrophages  or  their  pre-
cursors, monocytes, are now thought to be part of the im-
m u n e  s y s t e m ,  d e f e n d i n g  t h e  b r a i n  a g a i n s t  i n f e c t i o n  a n d  
injury. Microglia are the macrophages of the brain and are 
the first responders to CNS injury, but exactly which signal 
triggers microglial reactivity is not fully understood. The acti-
vating signals may include changes in neuronal transmission 
or  the  appearance  of  NO  or  proinflammatory  cytokines. 
Substantiation  indicates  that  central  glial  activation  depends 
on  nerve  inputs  from  the  site  of  injury  and  the  release  of 
chemical mediators. Glia, being the secret player in the neu-
roinflammation and neuropathic pain, could be exploited to 
provide new research avenues for therapeutic pain control. 
Taking into account both the protective and the pathological 
effects of activated glia will be a key to the development of 
effective  therapeutics.  Although  knowledge  of  the  develop-
ment  and  differentiation  of  glial  cells  has  significantly  in-
c r e a s e d  i n  r e c e n t  y e a r s ,  t h e r e  a r e  s t i l l  m a n y  u n a n s w e r e d  
questions regarding the consequential neuroinflammation and 
neuropathic pain subsequent to the neuronal injury via glial 
cell  (microglial  and  astrocytic)  activation. 
    Therapies directed at activated glia hold promise for new 
approaches to intractable pain. To expedite the goal of devel-
oping new diagnostic tools and new therapies for intractable 
pain, it is important to allow the cross-fertilization of ideas 
t o  o c c u r  b e t w e e n  p r e c l i n i c a l  a n d  c l i n i c a l  r e s e a r c h e r s .  I t  i s  
high time that neuroscience research focused on the charac-
terization of the glial phenotypes in the circumstances of in-
flammation,  nerve  injury  and  their  correlation  with  pain 
behavior. It can lead to the development of new therapeutic 
strategies by targeting both spinal glial cells and bone mar-
row-derived macrophages for effective pain relief. Finally, it 
can be concluded that glial cells act as orchestrators in the 
tetrapartite synapse and control of their activation state is cru-
cial  to  the  integrity  of  CNS  function.Glia in Neuropathic Pain and Inflammation
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